Virtual panel discussion | Research connects: Understanding lecanemab, a B.C. perspective
British Columbia
Thu, Mar 30, 7:00 pm - 8:00 pm
Online:
Click here to register.
Join us for an informative conversation between Jen Lyle, CEO of the Alzheimer Society of B.C., and Dr. Robin Hsiung, Associate Professor in Neurology at UBC as they discuss what lecanemab is, how it works] and what its approval in the U.S. means for British Columbians affected by dementia.
In January 2023, the U.S. FDA approved lecanemab as a treatment for individuals living with early-stage Alzheimer’s disease. Join us for an informative conversation between Jen Lyle, CEO of the Alzheimer Society of B.C., and Dr. Robin Hsiung, Associate Professor in Neurology at UBC as they discuss what lecanemab is, how it works] and what its approval in the U.S. means for British Columbians affected by dementia.